Biogen Inc (BIIB)

Index:

$ 142.50

By Abigail Townsend

Date: Wednesday 20 Oct 2021

(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.

Biogen shares soar as FDA approves Alzheimer's d...	08-Jun-2021	ShareCast
Biogen and Sage ink $1.5bn deal to develop anti-...	27-Nov-2020	ShareCast
US open: Wall Street flops as investors keep yan...	22-Mar-2019	ShareCast
Biogen dives after canning Alzheimer's drug trials	21-Mar-2019	ShareCast
Biogen selling Denmark plant to Fujifilm in $890...	12-Mar-2019	ShareCast

Elan says federal judge ruled it broke terms of ...	04-Sep-2009	Chicago Tribune
Johnson & Johnson Buys Access to an Alzheimer’s ...	03-Jul-2009	New York Times
Icahn Places Two Allies on the Biogen Idec Board	04-Jun-2009	New York Times
Pfizer Said to Be Closing In on Deal for Wyeth	24-Jan-2009	New York Times
Business News In Brief	31-Oct-2008	BayArea.com

Johnson & Johnson Buys Access to an Alzheimer’s ...	04-Jul-2009	Intl Herald Tribune
FedEx to take charges of $1.2 billion in its fou...	04-Jun-2009	LA Times
Wyeth Deal May Slow Pfizer Biotech Acquisitions	27-Jan-2009	New York Times
A Rough Week With a Sedate Conclusion	02-Aug-2008	New York Times
Stocks tumble as data, Greenspan warning deepen ...	01-Aug-2008	LA Times

Stock Watch: Emerging Public Company to Receive ...	31-Mar-2006	Marketwired
DailyStockPix.com Features HS3 Technologies, Inc...	09-Mar-2006	Marketwired
Seven Summits Research Releases Alerts on XMSR, ...	16-Feb-2006	PR Newswire
FDA Approves Rituxan(R) Plus CHOP or Other Anthr...	10-Feb-2006	PR Newswire

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.